C-LECTA GMBH

Their core work

C-LECTA is a Leipzig-based industrial biotechnology SME specializing in enzyme engineering and biocatalysis for pharmaceutical and chemical manufacturing. They develop and supply engineered enzymes that replace traditional chemical processes with cleaner, more efficient biological alternatives. Their work spans from plug-and-play enzyme solutions for pharma companies to cell-free synthetic biology platforms, positioning them as a bridge between academic enzyme research and industrial-scale bio-based production.

What they specialise in

How they've shifted over time

C-LECTA's early H2020 work (2015-2017) centered on making existing enzyme technology more accessible to the pharmaceutical industry — essentially productizing biocatalysis for established markets. By 2019, their focus shifted decisively toward synthetic biology and metabolic engineering, joining ambitious cell factory projects and exploring cell-free systems. This trajectory suggests a company moving upstream from applied enzyme supply toward designing biological production systems from scratch.

C-LECTA is evolving from an enzyme service provider into a synthetic biology platform company, which makes them increasingly relevant for bio-based manufacturing consortia.

How they like to work

C-LECTA balances leadership and partnership equally, coordinating 2 of their 4 projects. With 32 unique partners across 11 countries from just 4 projects, they operate in medium-to-large consortia and show a broad networking approach rather than reliance on repeat partners. As an SME that both leads and contributes, they are likely pragmatic collaborators who bring commercial focus to research-heavy consortia.

C-LECTA has built a surprisingly wide network for a small company — 32 unique partners across 11 countries from only 4 projects. Their collaborations span across Western and Northern Europe, reflecting strong integration into the EU biotech research ecosystem.

What sets them apart

C-LECTA sits at the commercially sharp end of industrial biotechnology — they are not a research lab but a product-oriented SME that turns enzyme science into industrial tools. Their dual capability in both classical biocatalysis and emerging synthetic biology makes them a rare partner who can bridge lab-scale metabolic engineering with market-ready bio-processes. For consortium builders, they bring the commercial validation and scale-up perspective that purely academic partners cannot.

Highlights from their portfolio

• PlugBioIn
  Their largest funded project (EUR 476K) as coordinator, directly targeting pharma industry adoption of biocatalysis — shows their core commercial mission.
• SHIKIFACTORY100
  Ambitious multi-year project aiming to produce 100 compounds via cell factories — marks C-LECTA's entry into large-scale synthetic biology consortia.
• BOB
  Innovation Associate project coordinated by C-LECTA to explore cell-free synthetic biology business opportunities — signals their strategic pivot toward next-generation biotech.